FSTL3
Follistatin-related protein 3
Protein Summary
Isoform 1 or the secreted form is a binding and antagonizing protein for members of the TGF-beta family, such us activin, BMP2 and MSTN. Inhibits activin A-, activin B-, BMP2- and MSDT-induced cellular signaling; more effective on activin A than on activin B. Involved in bone formation; inhibits osteoclast differentiationc. Involved in hematopoiesis; involved in differentiation of hemopoietic progenitor cells, increases hematopoietic cell adhesion to fibronectin and seems to contribute to the adhesion of hematopoietic precursor cells to the bone marrow stroma. Isoform 2 or the nuclear form is probably involved in transcriptional regulation via interaction with MLLT10. Follistatin-like 3 is a secreted glycoprotein of the follistatin-module-protein family. It may have a role in leukemogenesis. [provided by RefSeq, Jul 2008]
- ENST00000166139
- ENSP00000166139
- ENSG00000070404
- FLRG
- FLRG
- FSRP
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
biological process | 0.88 | ||
transcription factor | 0.64 | ||
gene perturbation | 0.61 | ||
tissue sample | 0.61 | ||
small molecule perturbation | 0.59 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 133.38 (req: < 5)
Gene RIFs: 47 (req: <= 3)
Antibodies: 183 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 133.38 (req: >= 5)
Gene RIFs: 47 (req: > 3)
Antibodies: 183 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 19
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0